Loading...
TNXP logo

Tonix Pharmaceuticals Holding Corp.NasdaqGS:TNXP Stock Report

Market Cap US$176.5m
Share Price
US$11.07
US$46.25
76.1% undervalued intrinsic discount
1Y-71.8%
7D-9.9%
1D
Portfolio Value
​
View

Tonix Pharmaceuticals Holding Corp.

NasdaqGS:TNXP Stock Report

Market Cap: US$176.5m

Tonix Pharmaceuticals Holding (TNXP) Stock Overview

A fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. More details

TNXP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 42.38% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market


TNXP Community Fair Values

Create Narrative

See what 70 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Tonix Pharmaceuticals Holding Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tonix Pharmaceuticals Holding
Historical stock prices
Current Share PriceUS$11.07
52 Week HighUS$69.97
52 Week LowUS$10.87
Beta1.68
1 Month Change-21.43%
3 Month Change-21.88%
1 Year Change-71.76%
3 Year Change-99.80%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Mar 17

Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum

Summary Tonix Pharmaceuticals reported Q4 GAAP EPS of -$3.98 (miss), but revenue surged 109% YoY to $5.39M, beating consensus by $2.42M. Early Tonmya launch metrics show promising initial uptake, with 4,200 prescriptions and 1,500+ prescribers, but revenue conversion remains uncertain due to pending insurance coverage. Operating expenses hit $138.8M in FY25, driving a net loss of $124M, though cash reserves doubled to $207.6M, supporting operations into Q1 2027. TNXP trades at a negative enterprise value, reflecting skepticism about Tonmya's commercial ramp and future cash flows; I maintain a cautious hold rating pending clearer prescription growth. Read the full article on Seeking Alpha
Analysis Article • Dec 01

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Aug 14

Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation

NasdaqCM:TNXP 1 Year Share Price vs Fair Value Explore Tonix Pharmaceuticals Holding's Fair Values from the Community...

Shareholder Returns

TNXPUS BiotechsUS Market
7D-9.9%-1.7%-2.5%
1Y-71.8%26.1%22.7%

Return vs Industry: TNXP underperformed the US Biotechs industry which returned 26.6% over the past year.

Return vs Market: TNXP underperformed the US Market which returned 22.8% over the past year.

Price Volatility

Is TNXP's price volatile compared to industry and market?
TNXP volatility
TNXP Average Weekly Movement11.8%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: TNXP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: TNXP's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2007142Seth Ledermanwww.tonixpharma.com

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Tonix Pharmaceuticals Holding Corp. Fundamentals Summary

How do Tonix Pharmaceuticals Holding's earnings and revenue compare to its market cap?
TNXP fundamental statistics
Market capUS$176.46m
Earnings (TTM)-US$147.39m
Revenue (TTM)US$17.56m
10.1x
P/S Ratio
-1.2x
P/E Ratio

Is TNXP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TNXP income statement (TTM)
RevenueUS$17.56m
Cost of RevenueUS$7.28m
Gross ProfitUS$10.28m
Other ExpensesUS$157.67m
Earnings-US$147.39m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-9.25
Gross Margin58.56%
Net Profit Margin-839.52%
Debt/Equity Ratio0%

How did TNXP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/08 04:59
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tonix Pharmaceuticals Holding Corp. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Chiara RussoBrean Capital Historical (Janney Montgomery)
David BuckB. Riley Securities, Inc.